Report from the NC3Rs, in collaboration with the ABPI and MHRA, explores how New Approach Methodologies (NAMs) can transform the way medicines are developed – harnessing cutting edge human-relevant technologies and reducing reliance on animal testing.
New approach methodologies, more commonly known as NAMs, are technologies that replace or reduce the use of animals in safety testing. They include advanced in vitro models such as organoids and organ-on-a-chip systems, in silico tools including AI and modelling approaches, and other human-relevant approaches that are already contributing to decision-making across the medicines development pipeline.